MX2023012447A - Ergolinas novedosas y metodos para tratar los desordenes del humor. - Google Patents
Ergolinas novedosas y metodos para tratar los desordenes del humor.Info
- Publication number
- MX2023012447A MX2023012447A MX2023012447A MX2023012447A MX2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A MX 2023012447 A MX2023012447 A MX 2023012447A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- mood disorders
- ergolines
- novel
- treating mood
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179053P | 2021-04-23 | 2021-04-23 | |
| US202263308376P | 2022-02-09 | 2022-02-09 | |
| PCT/US2022/026186 WO2022226408A1 (en) | 2021-04-23 | 2022-04-25 | Novel ergolines and methods of treating mood disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012447A true MX2023012447A (es) | 2023-10-31 |
Family
ID=81648213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012447A MX2023012447A (es) | 2021-04-23 | 2022-04-25 | Ergolinas novedosas y metodos para tratar los desordenes del humor. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368151A1 (https=) |
| EP (1) | EP4326718A1 (https=) |
| JP (1) | JP2024516174A (https=) |
| KR (1) | KR20240019091A (https=) |
| AU (1) | AU2022262659A1 (https=) |
| BR (1) | BR112023021970A2 (https=) |
| CA (1) | CA3223210A1 (https=) |
| IL (1) | IL307880A (https=) |
| MX (1) | MX2023012447A (https=) |
| WO (1) | WO2022226408A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230116703A1 (en) * | 2021-04-23 | 2023-04-13 | Gilgamesh Pharmaceuticals, Inc. | Novel ergolines and methods of treating mood disorders |
| EP4329759A4 (en) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| JP7846211B2 (ja) | 2021-08-19 | 2026-04-14 | デフィニウム セラピューティクス ユーエス， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤 |
| JP2025525375A (ja) * | 2022-06-20 | 2025-08-05 | マインド メディシン， インコーポレイテッド | 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体 |
| US20240239789A1 (en) * | 2022-12-31 | 2024-07-18 | Ceruvia Lifesciences Llc | Salts of 2-bromolysergic acid diethylamide |
| WO2024229454A2 (en) * | 2023-05-04 | 2024-11-07 | Gilgamesh Pharmaceuticals, Inc. | Novel ergolines and methods of treating mood disorders |
| WO2025194238A1 (en) * | 2024-03-22 | 2025-09-25 | Blife Therapeutics Inc. | 2-bromo-lsd salts and polymorphs |
| WO2025235800A1 (en) | 2024-05-08 | 2025-11-13 | Cy Biopharma Ag | Ergoline derivatives and uses thereof |
| WO2025235784A2 (en) * | 2024-05-08 | 2025-11-13 | Cy Biopharma Ag | Ergoline derivatives and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2438259A (en) * | 1948-03-23 | D-lysergic acid diethyl amide | ||
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| WO2021076572A1 (en) * | 2019-10-14 | 2021-04-22 | The Regents Of The University Of California | Ergoline-like compounds for promoting neural plasticity |
| US20230286975A1 (en) * | 2020-07-07 | 2023-09-14 | Compass Pathfinder Limited | Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof |
-
2022
- 2022-04-25 US US18/287,980 patent/US20240368151A1/en active Pending
- 2022-04-25 CA CA3223210A patent/CA3223210A1/en active Pending
- 2022-04-25 EP EP22723308.7A patent/EP4326718A1/en active Pending
- 2022-04-25 MX MX2023012447A patent/MX2023012447A/es unknown
- 2022-04-25 WO PCT/US2022/026186 patent/WO2022226408A1/en not_active Ceased
- 2022-04-25 IL IL307880A patent/IL307880A/en unknown
- 2022-04-25 JP JP2023564585A patent/JP2024516174A/ja active Pending
- 2022-04-25 AU AU2022262659A patent/AU2022262659A1/en active Pending
- 2022-04-25 KR KR1020237040483A patent/KR20240019091A/ko active Pending
- 2022-04-25 BR BR112023021970A patent/BR112023021970A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL307880A (en) | 2023-12-01 |
| JP2024516174A (ja) | 2024-04-12 |
| WO2022226408A1 (en) | 2022-10-27 |
| US20240368151A1 (en) | 2024-11-07 |
| KR20240019091A (ko) | 2024-02-14 |
| BR112023021970A2 (pt) | 2023-12-26 |
| EP4326718A1 (en) | 2024-02-28 |
| CA3223210A1 (en) | 2022-12-27 |
| AU2022262659A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012447A (es) | Ergolinas novedosas y metodos para tratar los desordenes del humor. | |
| MX2025013117A (es) | Ergolinas novedosas y métodos de tratamiento de trastornos del estado de ánimo | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| WO2024091506A3 (en) | Novel ergolines and methods of treating mood disorders | |
| MX2025004367A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| EP4295846A3 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| MX2025006196A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
| MX395214B (es) | Composiciones novedosas y metodos | |
| GEP20247679B (en) | Bicyclic heterocycles as fgfr inhibitors | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2025011533A (es) | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| AU2020215150A8 (en) | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders | |
| MX2024001243A (es) | Composiciones y metodos para el tratamiento de melanoma. | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2019004070A (es) | Sistema de extraccion de un sistema de circuito cerrado. | |
| GEP20257840B (en) | Tyk2 pseudokinase ligands | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2022003243A (es) | Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos. | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| MX2025007184A (es) | Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos | |
| MX2023004942A (es) | Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer |